Intravenous arketamine for treatment-resistant depression: open-label pilot study-Reference-Cited by-同舟云学术

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Published:2020-02-20 Issue:3 Volume:271 Page:577-582
ISSN:0940-1334
Container-title:European Archives of Psychiatry and Clinical Neuroscience
language:en
Short-container-title:Eur Arch Psychiatry Clin Neurosci

Author:

Leal Gustavo C.,Bandeira Igor D.,Correia-Melo Fernanda S.,Telles Manuela,Mello Rodrigo P.,Vieira Flavia,Lima Cassio S.,Jesus-Nunes Ana Paula,Guerreiro-Costa Lívia N. F.,Marback Roberta F.,Caliman-Fontes Ana Teresa,Marques Breno L. S.,Bezerra Marília L. O.,Dias-Neto Alberto L.,Silva Samantha S.,Sampaio Aline S.,Sanacora Gerard,Turecki Gustavo,Loo Colleen,Lacerda Acioly L. T.,Quarantini Lucas C.

Funder

Programa de Pesquisa para o SUS

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00406-020-01110-5.pdf

Reference31 articles.

1. Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. https://doi.org/10.1016/S0006-3223(99)00230-9

2. Caddy C, Amit BH, McCloud TL et al (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011612.pub2

3. Xu Y, Hackett M, Carter G et al (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyv124